Anxo Pharmaceutical Co., Ltd.
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, o… Read more
Anxo Pharmaceutical Co., Ltd. (6677) - Total Assets
Latest total assets as of June 2025: NT$2.05 Billion TWD
Based on the latest financial reports, Anxo Pharmaceutical Co., Ltd. (6677) holds total assets worth NT$2.05 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anxo Pharmaceutical Co., Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Anxo Pharmaceutical Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Anxo Pharmaceutical Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Anxo Pharmaceutical Co., Ltd.'s total assets of NT$2.05 Billion consist of 41.7% current assets and 58.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 17.0% |
| Accounts Receivable | NT$212.59 Million | 10.1% |
| Inventory | NT$262.42 Million | 12.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$9.84 Million | 0.5% |
| Goodwill | NT$36.61 Million | 1.7% |
Asset Composition Trend (2019–2024)
This chart illustrates how Anxo Pharmaceutical Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anxo Pharmaceutical Co., Ltd.'s current assets represent 41.7% of total assets in 2024, an increase from 0.3% in 2019.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2024, up from 9.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 12.5% of total assets.
Anxo Pharmaceutical Co., Ltd. Competitors by Total Assets
Key competitors of Anxo Pharmaceutical Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Anxo Pharmaceutical Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Anxo Pharmaceutical Co., Ltd. generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Anxo Pharmaceutical Co., Ltd. is currently not profitable relative to its asset base.
Anxo Pharmaceutical Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 1.78 | 0.72 |
| Quick Ratio | 1.14 | 1.24 | 0.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$333.14 Million | NT$ 417.25 Million | NT$ -139.38 Million |
Anxo Pharmaceutical Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Anxo Pharmaceutical Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.04 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | NT$2.11 Billion |
| Market Capitalization | $16.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anxo Pharmaceutical Co., Ltd.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Anxo Pharmaceutical Co., Ltd.'s assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anxo Pharmaceutical Co., Ltd. (2019–2024)
The table below shows the annual total assets of Anxo Pharmaceutical Co., Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.11 Billion | -5.00% |
| 2023-12-31 | NT$2.22 Billion | +12.38% |
| 2022-12-31 | NT$1.97 Billion | +2.87% |
| 2021-12-31 | NT$1.92 Billion | +0.30% |
| 2020-12-31 | NT$1.91 Billion | +0.18% |
| 2019-12-31 | NT$1.91 Billion | -- |